Mandate Vicore Pharma Holding acquires INIM Pharma

July 03, 2018

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

New assignment for Anders Leissner

Anders Leissner has been appointed by the Swedish government as chairman of the War Insurance Board.
February 26, 2021

Vinge is awarded “The Top Firm in Sweden” in WTR 1000’s latest ranking

Vinge receives the highest ranking in the World Trademark Review list of the year’s rankings. The firm obtains the Guide’s foremost ranking, which also highlights specific experts.
February 18, 2021

Insurance services in Sweden – a summary 2021

Vinge’s insurance team has written a brief summary of some of the main features of the Swedish regulations affecting foreign insurers with existing or contemplated business activities in Sweden.
February 09, 2021